NewAmsterdam Pharma Company NAMS Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's net change in cash?
- NewAmsterdam Pharma Company (NAMS) reported net change in cash of -$31.05M in Q1 2026.
- How has NewAmsterdam Pharma Company's net change in cash changed year-over-year?
- NewAmsterdam Pharma Company's net change in cash decreased by 14.6% year-over-year, from -$27.09M to -$31.05M.
- What is the long-term trend for NewAmsterdam Pharma Company's net change in cash?
- Over 3 years (2021 to 2025), NewAmsterdam Pharma Company's net change in cash has grown at a 74.5% compound annual growth rate (CAGR), from $55.17M to -$293.18M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.